Skip to main content

Table 3 Best overall response (per RECIST) for patients treated in Phase 2 with IL-21 (30 mcg/kg) plus sorafenib (starting at 400 mg twice daily)

From: Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study

RECIST response

Investigator assessment (N = 33)

Independent review (N = 33)

Complete response

0

0

Partial response

6 (18%)

7 (21%)

Stable disease

22 (67%)

20 (61%)

Progressive disease

4 (12%)

4 (12%)

Unavailable*

1 (3%)

2 (6%)

  1. *Includes 1 subject who discontinued for toxicity prior to disease reassessment by both investigator and independent review and 1 subject with progressive disease on imaging not sent for independent review. All objective responses were confirmed on a subsequent imaging study.
Back to article page